February 14, 2022

In this MD Newsline exclusive interview with dermatologist Dr. Victoria Barbosa, we discuss disparities in diagnosing and treating central centrifugal cicatricial alopecia (CCCA) before and during the COVID-19 pandemic. MD Newsline: What disparities in diagnosing and treating CCCA have you observed in your clinical practice? Dr. Victoria Barbosa: “Recent research has shown us that CCCA...

The U.S. Food and Drug Administration approved Rinvoq (upadacitinib) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older, the manufacturer announced Friday. The approval is indicated for patients with atopic dermatitis that did not respond to previous treatment and is not well controlled with other medications or when the use...

In this MD Newsline exclusive interview with dermatologist Dr. Victoria Barbosa, we discuss the latest research on central centrifugal cicatricial alopecia (CCCA) diagnosis, prognosis, and treatment. We also discuss how to improve diversity and inclusion in dermatology clinical trials. MD Newsline: Is there any research that excites you or that you think is important for physicians...

In this MD Newsline exclusive interview with dermatologist Dr. Victoria Barbosa, we discuss Dr. Barbosa’s central centrifugal cicatricial alopecia (CCCA) treatment strategy. We also discuss the many rewards of treating CCCA. MD Newsline: What is your treatment strategy for CCCA? Dr. Victoria Barbosa: “I have a two-pronged approach to treating CCCA. First, we have to address the...

In this MD Newsline exclusive interview with dermatologist Dr. Victoria Barbosa, we discuss how to address implicit bias in dermatology. MD Newsline: How can dermatologists address implicit bias in their practice? How might their doing so improve healthcare for underserved communities?  Dr. Victoria Barbosa: “The first step to addressing implicit biases is to recognize that...